Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients With Primary and Secondary Myelofibrosis
NCT02251821Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Oct 2014
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in primary myelofibrosis (PMF) and secondary myelofibrosis (SMF), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Overall Survival at 2 years. Started Oct 2014; status: completed.
02
Drugs
03
Conditions
primary myelofibrosis (PMF)secondary myelofibrosis (SMF)
Beyond the preview
Go deeper on NCT02251821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02251821.